The estimated Net Worth of Kenneth L Horton is at least $4.14 Миллион dollars as of 10 February 2022. Mr Horton owns over 143,126 units of Senseonics Inc stock worth over $479,544 and over the last 12 years he sold SENS stock worth over $3,664,460.
Mr has made over 5 trades of the Senseonics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 143,126 units of SENS stock worth $352,090 on 10 February 2022.
The largest trade he's ever made was selling 143,126 units of Senseonics Inc stock on 10 February 2022 worth over $352,090. On average, Mr trades about 9,374 units every 136 days since 2012. As of 10 February 2022 he still owns at least 1,217,425 units of Senseonics Inc stock.
You can see the complete history of Mr Horton stock trades at the bottom of the page.
Kenneth L. Horton is the Gen. Counsel & Corp. Devel. Advisor at Senseonics Inc.
Mr Horton is 54, he's been the Gen. Counsel & Corp. Devel. Advisor of Senseonics Inc since . There are 8 older and 7 younger executives at Senseonics Inc. The oldest executive at Senseonics Holdings Inc is Dr. Francine Ratner Kaufman M.D., 70, who is the Chief Medical Officer & Director.
Kenneth's mailing address filed with the SEC is C/O SENSEONICS HOLDINGS, INC., 20451 SENECA MEADOWS PARKWAY, GERMANTOWN, MD, 20876.
Over the last 9 years, insiders at Senseonics Inc have traded over $36,720,504 worth of Senseonics Inc stock and bought 30,963,337 units worth $56,759,340 . The most active insiders traders include Peter J Barris, M James Barrett и Douglas A Roeder. On average, Senseonics Inc executives and independent directors trade stock every 45 days with the average trade being worth of $313,683. The most recent stock trade was executed by Sharon Larkin on 7 September 2023, trading 30,889 units of SENS stock currently worth $18,842.
senseonics, inc. is a medical device startup company in germantown, maryland, usa (near washington, dc) developing transformative glucose monitoring products that are intended to enable people with diabetes to confidently live their lives with ease. utilizing breakthrough fluorescence sensing technology, the senseonics continuous glucose monitoring ("cgm") system is being designed to be the first fully implantable cgm that is highly accurate and stable throughout its long sensor life. the system consists of a very small sensor implanted under the skin, an external transmitter, and a mobile medical application, which allows for discreet, easy access to real-time glucose measurements without the need for a dedicated receiver.
Senseonics Inc executives and other stock owners filed with the SEC include: